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Abstract
Introduction: This prospective cohort study aimed to assess the influence of stem cell therapy (SCT) on health-
related quality of life (HRQOL) by using the SF-36 v2 and to elucidate the influence of objective clinical variables
on subjective HRQOL.
Methods: The study included 100 chronic liver disease patients (50 received SCT, and 50 received supportive
medical treatment (SMT)). Both groups completed a modified SF-36 v2 form before therapy and at 1-, 3-, 6-, and
12-month intervals. Fifty healthy Egyptian volunteers were enrolled in the study and completed the SF-36 v2 form
once.
Results: Both SCT and SMT groups showed significantly lower pretherapy SF 36 v2 scores compared with
healthy volunteers. In SCT-treated patients, limited complications were encountered (SF-36 v2 scores showed
significant improvement in all domains throughout the follow-up period) compared with the deterioration
shown by SMT patients after therapy. A significant association was detected between SF-36 v2 scores and
laboratory data in SCT patients during the first month after therapy. The grade of ascites improved during the
follow-up in SCT compared with SMT patients. The mean survival time was 277.56 days (95% CI, 246.217 to
308.903) for SMT and 359.300 days (95% CI, 353.022 to 365.578) for SCT patients (log rank, 0.00). Stem cell-
treated patients showed no malignancies.
Conclusions: SCT positively affects health-related quality of life in cirrhosis patients. The survival rate was
significantly improved after SCT.
Introduction
Chronic liver disease (CLD) leads annually to disability of
hundreds of thousands of patients worldwide. Cell therapy
with embryonic fetal, mononuclear, mesenchymal stromal
cells is the most advanced front of modern biotechnology
and medicine [1]. An important part of treatment is to
improve the health-related quality of life (HRQoL) and to
support the ability to cope with stressors related to disease
[2]. The Short Form-36 (SF-36) health survey is a generic
health-status measurement consisting of 36 items in eight
domains; these eight scales are then combined to form
two distinct higher-ordered clusters, the physical and
mental health components, which have demonstrated
good reliability and validity in chronic disease populations,
including in patients with chronic liver diseases. In clinical
practice, HRQoL prediction from objective variables is
necessary and may be useful. For that purpose, the relation
between subjective HRQoL scores and objective clinical
variables, such as the presence of ascites, the status of
hepatocellular carcinoma (HCC), and laboratory data,
should be further analyzed [3].
Many health surveys and scoring systems are available,
but not enough published data are available worldwide
on the quality-of-life assessment for the patients receiv-
ing stem cell therapy [4]. We studied the effect of stem
cell therapy on HRQoL by using the SF-36 v2.
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Materials and methods
Study objectives
We conducted this study to elucidate the influence of
stem cell therapy on HRQoL by using the SF-36 v2 in
patients with end-stage liver disease, and to detect the
influence of the objective clinical variables on the sub-
jective HRQoL scores.
Methods and study design
This prospective cohort study was conducted after being
approved by the local Ethics Committees and Health
Authorities as a continuation of the workup of our pre-
viously published study [5]. A written informed consent
was obtained from all patients and normal control sub-
jects before enrolment in the study, and the ethical
committee of the National Cancer Institute and Kasr
Alini hospital, Cairo University, approved the protocol,
which was in accordance with the ethical guidelines of
the Declaration of Helsinki (Organization No.
IORG0003381; IRB 0004025, Valid to 04 Dec, 2013).
We modified the SF-36 v2 survey questionnaire, which
was originally in the English language. It was translated
into Arabic. Some questions were repeated with the same
meaning, especially in the Arabic formula, so the survey
was slightly modified before its distribution to be easily
understood. This allowed more accurate and specific
responses from the Egyptian population. We met our can-
didates personally or talked to them by telephone to parti-
cipate in the study; this step agrees with that made in
other studies [6,7].
The questionnaire was carefully explained to the candi-
dates; the period of each survey was from 10 to15 minutes.
The questionnaire was used to assess liver disease and the
effect of stem cell transplantation on the quality of life of
patients. This agrees with that done in the studies of El
Garem et al. [8], El-Serafy et al. [6], and Saly et al. [7] All
patients were asked to complete the survey before and
after therapy at a fixed time points, together with labora-
tory investigations at the same time; this agrees with what
was done by El Garem et al. [8].
Patients’ demographics
Patient selection and data collection
Patients of our study (n = 100) were selected from those
with advanced posthepatitis C virus liver cirrhosis and
WHO performance score of less than 2, attending the
hepatology clinic Kasr Alini Hospital, Cairo University, (a
nonprofit hospital), during the period from June 2009 to
May 2010, to receive standard care according to their
needs, but with no great improvement in their biochemical
profile or the ascites status on follow-up. Patients who
matched the inclusion criteria for stem cell therapy were
assigned to SCT group I (n = 50) to receive SCT only, and
the other patients who had not received SCT either
because they refused or they were uncooperative were
assigned to the SMT group II (n = 50) to receive the stan-
dard care according to their needs, including human albu-
min transfusion, fresh plasma, and vitamin K, according to
the patients’ needs, and were followed up through our
study together with those of the SCT group (I). A group of
apparently healthy volunteers free from any chronic liver
disease (n = 50) were included in our study to provide the
normal range of scores of the SF-36 v2 questionnaire of
the healthy Egyptian population to be compared with the
studied group of patients. Uncooperative patients and
patients with any other chronic diseases, HCC, or severe
bleeding tendency, were excluded from our study.
After the patient’s informed-consent form was signed,
the following data were collected from patients involved
in this study. Demographic features of the patients
including age and sex, detailed medical history, findings
at physical examination, laboratory tests: (complete blood
count, liver-function test, aspartate aminotransferase
(AST), alanine transaminase (ALT), alkaline phosphatase
(ALP), serum bilirubin, prothrombin concentration, INR,
and serum creatinine. Conventional abdominal ultraso-
nography was performed.
All patients involved in our study were asked to com-
plete the SF-36 questionnaire before therapy, and at four
posttherapy time points (1, 3, 6 months, and at 1 year),
allowing changes in individual responses over time as well
as group responses at specific time points to be analyzed
and compared between both groups, together with per-




Days 1 to 5 Patients received a daily subcutaneous
injection of 300 g of G-CSF (Neupogen; Roche Pharma-
ceutical) (Made in Switzerland by F. Hoffmann-La
Roche Ltd, Basel) for 5 days to increase the numbers of
circulating hematopoietic stem cells.
Day 6 Patients underwent a leukapheresis procedure in
the Department of Hematology, National Cancer Insti-
tute. After the collection, the cells were transferred to
the stem cell laboratory for immunomagnetic separation
of the CD34+ stem cell population. The CD34+ cells
were placed in culture for amplification and differentia-
tion from day 6 to day 13.
Laboratory methods
Cell source, isolation, and cultivation
G-CSF-mobilized peripheral blood (200 ml) was obtained
with leukapheresis, and CD34+ cells were isolated from
that blood by adding one volume of blood to five to 10
volumes of the lysis buffer (155 mM NH4Cl, 10 mM
KHCO3, and 0.1 mM EDTA) for 30 minutes at 4°C to
remove RBCs and to separate mononuclear cells (MNCs).
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The collected MNCs were washed twice with buffer (phos-
phate-buffered saline (PBS), pH 7.4, supplemented with
0.5% bovine serum albumin and 5 mM EDTA), and cen-
trifuged at 1,500 rpm for 10 minutes. The MNCs were
counted, adjusted to 2 × 109/ml, and centrifuged. CD34+
cells were isolated by using the CD34+ cell-selection kit
(CliniMacs, Germany). The cells were cultured in MEM/
Ham F12 (1:1) containing 10% BSA, 1% penicillin/strepto-
mycin, 1 ng/ml GM-CSF, and growth factor (multiplica-
tion stimulating factor: liver extract, 20 mg/ml; Sigma Lot
35F-0165) and incubated for 5 to 7 days at 37°C in 5%
CO2. Morphology of the cultured CD34
+ cells was assayed
with phase-contrast microscopy.
Day 13 Patients were admitted for collection of blood
for CBC and liver-function tests. The patients were
infused with approximately 1 billion expanded CD34+
stem cells suspended in normal physiologic saline into
either the portal vein, if hepatopedal flow, or hepatic
artery, if hepatofugal flow, under ultrasound or CT gui-
dance by using complete aseptic precautions with an
18-G needle and the 3.5-MHz probe of the ultrasono-
graphy machine. The technique used is described in
detail in our previous publication [5].
Statistical methods
SF-v2 questionnaire scores were calculated for each
patient in the three groups, and patient data were analyzed
by using SPSS 17.0 for Windows 7. Quantitative variables
were expressed as mean ± SD (standard deviation) and
compared by using Student t test, Mann-Whitney U, and
Kruskal-Wallis H test, when appropriate, whereas qualita-
tive variables were expressed in terms of numbers (fre-
quency) and percentage, compared between groups with
the c2 test. A general linear model with repeated measures
was performed with pairwise comparisons based on esti-
mated marginal means. Correlation coefficient was calcu-
lated by using Spearman rho and Pearson correlation, as
appropriate. A Kaplan-Meier curve was constructed to
calculate and compare the survival time for each group. A
P value is considered significant when < 0.05.
Results
Analyzing the data of the studied groups, we found statis-
tically significant differences regarding age and sex distri-
bution, residency, occupation, and marital status; their
demographic and clinical data are represented in Table 1.
The scores of all SF-36 questionnaire domains were calcu-
lated and compared between the three studied groups, and
the results are represented in Figure 1 and Table 2.
By following up the SCT group (I) of patients, after
stem cell therapy, it was found that both main domains,
PCS (physical component summary) and MCS (mental
component summary), increased progressively after ther-
apy up to the sixth month of follow up, and then they
showed no statistically significant change by the first year
after therapy. Still the mean value of the PCS in healthy
control group is greater than that of SCT group (I), and
this difference is statistically significant, with a P value =
0.00. No statistically significant difference was noted
between the values of corresponding MCS values
between both groups (Figure 2; Table 3).
The same applies for PF, RP, SF, and RE, in which the
score increased progressively during the months of follow-
up to the sixth month, and then it became stable; no sta-
tistically significant difference exists between the scores at
the sixth month and those at 1 year, and still the values of
both PF and SF in the healthy control group are greater
than the corresponding values after 1 year of follow-up in
the SCT group (I) of patients with a P value = 0.00 in
each. No statistically significant difference regarding RP
and RE values is apparent at the same periods of follow-up
between both groups.
For the BP and MH domains, the issue is a little bit dif-
ferent, the score increased significantly after one month of
therapy. No statistically significant changes were noted
afterward, and yet it was found that the scores of BP after
1 month of therapy in the SCT group (I) were less than
those of healthy control group, and the same applies to
the values of MH at the same period. The difference is sta-
tistically significant with a P value = 0.001, yet these scores
are also significantly greater than those of SMT group (II).
The SCT group (I) also reported a significant increase in
both GH and VT domain scores after 1 month of therapy;
then it insignificantly changed until the third month of fol-
low-up, and then both domains showed a statistically sig-
nificant increase in their scores by the sixth month, but
again, the scores were insignificantly changed. After that,
both domains showed no statistically significant changes
in their scores after 1 year of follow-up, yet still both
scores were significantly greater in the healthy volunteers
group than in the SCT group (I).
By following up the patients receiving standard care in
the SMT group (II) with the SF-36 v2, we noted a signifi-
cant deterioration in all the domain scores throughout the
follow-up period, which does not match the observed
improvement in the scores of patients treated with stem
cells, with a statistically significant difference between
both groups in all the domains.
Regarding ascites, patients of the SCT group (I) showed
continuous improvement throughout the follow-up per-
iod, represented in Figure 3.
To study the effect of diabetes mellitus in the SF-36
questionnaire, the patients of the SCT group (I) were
categorized into two groups. The first group was for
patients with diabetes mellitus, and the second group was
for patients with no diabetes mellitus. The results showed
no significant difference between both diabetes and non-
diabetes groups regarding the PCS and MCS score before
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and after therapy; both domains increased significantly
after therapy in both groups. Regarding the PCS domain
before therapy, both diabetes and nondiabetes groups
showed a statistically significant positive relation with
PCS after 1 and 3 months of follow-up. The same applies
to the MCS score, but the relation extends in the nondia-
betes group to show a statistically significant relation
between MCS before therapy and that after 6 months of
therapy.
The change in the laboratory data throughout the fol-
low-up period in the SCT group (I) is represented in
Figure 4 and Table 4, whereas those of our previous
study are represented in Figure 5.
In SCT group (I), the PCS domain at 1 year after ther-
apy is dependent on the AST value at the third month
after therapy, in which a significant positive relation is
seen: r = 0.33 with a P value of 0.009. The MCS domain
after 1 year of therapy is dependent on the ALT value
before therapy, in which a significant negative relation





Healthy volunteers Group III
(n = 50)
P value
Age (mean ± SD) 51.84 ± 7.57 50.36 ± 7.01 46.40 ± 10.77 > 0.05
Gender (%)
Male 42 (84%) 40 (80%) 40 (80%) > 0.05
Female 8 (16%) 10 (20%) 10 (20%)
Residency (%)
Urban 38 (76%) 39 (78%) 40 (80%) > 0.05
Rural 12 (24%) 11 (22%) 10 (20%)
Occupation (%)
Administrative, managerial, and professional 23 (46%) 23 (46%) 26 (52%) > 0.05
Other occupations 27 (54%) 27 (54%) 24 (48%)
Marital status (%)
Married 50 (100%) 50 (100%) 46 (92%) > 0.05
Unmarried 0 (0) 0 (0) 6 (8%)
Jaundice 24 22 > 0.05
History of encephalopathy 12 20 > 0.05
Weight loss 32 29 > 0.05
Peripheral erythema 42 39 > 0.05
Lower-limb edema 32 33 > 0.05
Figure 1 The eight SF-36 v2 domains scores among the
studied groups of patients. BP, bodily pain; group I, SCT group;
group II, SMT group; group III, healthy volunteers group; GH, general
health; MCS, mental component summary; MH, mental health; PCS,
physical component summary; PF, physical functioning; RE, role
emotional; RP, role physical; SF, social functioning; VT, vitality.
Table 2 The P value of comparisons of the SF-v2 domain
scores among the studied groups
SF-v2 P value SCT group (I) versus
healthy volunteers group (III)












BP, bodily pain; GH, general health; MCS, mental component summary; MH,
mental health; PCS, physical component summary; PF, physical functioning;
RE, role emotional; RP, role physical; SF, social functioning; VT, vitality.
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was detected with r = -0.268 and P value = 0.03. The
MCS domain after 6 months of therapy is dependent on
the AST value before therapy, in which a significant
negative relation was detected with r = -0.37 and P value
= 0.048. A significant positive relation was also detected
between PCS after 3 months of therapy and the value of
ALT before therapy, with r = 0.27 and P value = 0.03. A
significant positive relation was detected between the RP
after 1 year of therapy and the value of total bilirubin
before therapy, with r = 0.302 and P value = 0.017. A sig-
nificant positive relation was detected between RP after
1 year of therapy and the value of ALT after 1 month,
with r = 0.241 and P value = 0.046.
The overall survival of patients of both groups after
1 year of follow-up was 62% in the SMT group (II) and
94% in the SCT group (I), with a mean survival time of
277.56 days (95% CI, 246.217 to 308.903) for the SMT
group (II) and 359.300 days (95% CI, 353.022 to
365.578) for the SCT group (I). Time to death for both
groups is represented in the Kaplan-Meier curve with a
log rank of 0.00 (Figure 6).
Discussion
Cell-based therapy, including the use of stem cell therapy,
offers considerable hope for patients with end-stage liver
cell failure [9,10]. We report a prospective cohort study
using a quality-of-life survey, SF-36 v2, conducted on 50
posthepatitis C virus cirrhosis patients receiving stem cell
therapy at our center, to be compared with the survey
results conducted on a group of posthepatitis C virus cir-
rhosis patients (n = 50), receiving the standard line of care,
and a group of healthy blood donors (n = 50).
The overall compliance rate for survey completion in our
study was high (98%). This rate reflects our policy of moni-
toring all patients who received stem cell therapy for 1 year




Figure 2 Mean value of the eight domain scores of the SF-35 v2 on follow-up after stem cell therapy in group I. BP, bodily pain; group
I, SCT group; group II, SMT group; group III, healthy volunteers group; GH, general health; MCS, mental component summary; MH, mental health;
PCS, physical component summary; PF, physical functioning; RE, role emotional; RP, role physical; SF, social functioning; VT, vitality.
Table 3 The P value for comparison of SF-v2 domains in the follow-up period in group (I)
Follow-up periods P value for SF domains
PCS MCS PF RP BP GH VT SF RE MH
Before therapy versus 1 month after therapy 0.000 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
1 versus 3 months after therapy 0.000 0.002 0.00 0.00 0.06 0.00 0.14 0.008 0.00 0.49
3 versus 6 months after therapy 0.004 0.004 0.01 0.005 0.14 0.02 0.012 0.008 0.002 0.2
6 months versus 1 year after therapy 0.78 0.69 0.9 0.82 0.93 0.34 0.45 0.814 0.7 0.76
BP, bodily pain; GH, general health; MCS, mental component summary; MH, mental health; PCS, physical component summary; PF, physical functioning; RE, role
emotional; RP, role physical; SF, social functioning; VT, vitality.
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those scheduled visits. This policy differs from other qual-
ity-of-life reports used in similar studies in liver transplan-
tation patients [11,12], but we believe that this approach
provides maximum information regarding the impact of
stem cell therapy on cirrhosis patients at various time
points.
Our study was conducted in a nonprofit governmental
hospital where the patients are of low socioeconomic sta-
tus; this fact may influence their HRQoL scores and the
results of our study as well, which may differ from those
with patients attending a private hospital in Egypt.
The pretherapy SF-36 v2 scores of patients in SCT
group (I) were significantly below average as compared
with those of the healthy control subjects. This is an
expected finding because they are patients with end-stage
liver disease. In comparison of their scores with those of
patients in the SMT group (II), we found that PCS, GH,
BP, VT, and MH scores show no statistically significant
difference between the groups, but PF is significantly
greater in the SCT group (I), whereas MCS, RE, SF, and
RP are significantly greater in the SMT group (II).
Our patients found the overall stem cell therapy process
positive; this was reported through the consistent
improvement of the patients’ PCS and MCS scores in all
patients until the end of the first year of follow-up to
reach the average values of the healthy volunteers, indicat-
ing that stem cell therapy improves the HRQoL. Most of
the SF-36 eight domains (PF, RP, SF, RE, GH, and VT)
showed consistent improvement during the follow-up per-
iod in all patients back to pretherapy; this accords with
reports by other studies [13,14].
Regarding the laboratory data of patients in SCT group
(I), it was noticed that platelets and WBCs (white blood
cells) counts did not show any statistically significant
change during the follow-up period, but a significant
reduction in hemoglobin and albumin levels occurred in
the first month of follow-up; hemoglobin reached a steady
level until the end of the follow-up period, whereas
albumin showed a significant increase by the third month
of follow-up, but it decreased significantly again to reach a
steady value until the end of the follow-up period. This
result coincides with those of some published studies [5,6],
but does not agree with other published studies [10,14,15].
INR values continued to decrease significantly until
the third month of follow-up, but a marked significant
increase was observed by the end of the first year of fol-
low-up, which agrees with what was concluded by Lyra
et al. [13].
The total serum bilirubin levels continue to decrease up
to the sixth month of follow-up. Then they show a signifi-
cant increase by the end of the first year of follow-up, but
significantly less than its pretherapy level. These findings
are consistent with the results of other studies
[5,8,10,14,16,17].
For the liver enzymes, both AST and ALT levels showed
statistically significant changes during the period of fol-
low-up; at the first month after therapy, they decreased,
then increased by the third month, and then decreased
again by the sixth month, to increase by the end of the
first year of follow-up. It worth mentioning that the signif-
icant change in the biochemical profile and the ascites
grade in the SCT group (I) had markedly decreased the
need for receiving the standard line of care for such
patients, so the patients were managed accordingly.
In the SCT group (I), in comparing the change in the
clinical findings with changes in the quality of life, we
noticed that at 1 month, the quality of life scores was
improved together with laboratory results; this agrees with
that reported by Kondo et al. [3]. However, the liver
enzymes deteriorated after being improved after 3 months,
and the total bilirubin increased again after 6 months,
while all the quality-of-life domains continued to improve,
except for the BP and MH, which remained almost con-
stant after the first month. This is significantly less than
those of the normal healthy subjects, which means that
the quality-of-life domains are not affected by the changes
in the liver function, except in the early stage after stem
cell therapy, which does not agree with results reported by
El Garem et al. [6]. This may be attributed to the differ-
ence in the technique used for stem cell therapy; El Garem
injected 5 to 10 million cells in 10 ml under sonographic
guidance into the spleens of his patients.
Our result might be explained by the hypothesis that
the bodily pain subscale is a two-item scale that mea-
sures perception of pain and how much pain interferes
with normal work, including both outdoor work and
housework, where the score does not continue to
improve after the first month and becomes constant.
This may be due to mild significant elevation of liver
enzymes after the first month; moreover, some patients
develop mild to moderate ascites, which leads to
abdominal pain in some patients.

  None 
Figure 3 Progress of the degree of ascites in group (I) during
the follow-up period. Y axis represents the percentage of patients;
X-axis represents the time of the follow-up period, and the figure
represents the change of the degree of ascites during the follow-up
period.
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Figure 4 Changes that occurred in laboratory data during the follow-up period of group I. In the upper two graphs, the y-axis represents
the mean value of the tested parameter, and the x-axis represents the follow-up periods. Upper-left graph shows changes in the mean levels of
hemoglobin, total serum bilirubin, INR, and serum albumin, whereas the upper-right graph represents the mean values of both ALT and AST. The
lower-left graph represents the mean total leukocyte count; and the lower-right graph represents the mean platelet count.
Table 4 The P values of comparison of the laboratory data during the follow-up period in group (I)
Follow-up periods P value for lab data
Hemoglobin TLC Platelets Bilirubin ALT AST
Before therapy versus after 1 month 0.00 0.78 0.19 0.00 0.00 0.00
After 1 month versus after 3 months 0.285 0.06 0.25 0.00 0.00 0.00
After 3 months versus after 6 months 0.15 0.11 0.35 0.002 0.001 0.00
After 6 months versus after 1 year 0.97 0.16 0.303 0.00 0.013 0.00
ALT, alanine transaminase; AST, aspartate transaminase; TLC, total leukocyte count.
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Conversely, the mental health subscale is a five-item
scale that measures nervousness, happiness, depression,
peacefulness, and feeling so down-in-the-dumps. Its
score does not continue to increase after the first
month, and that may be attributed to the depression
and the nervousness that the end-stage liver disease
patients experience and directly affects their work; their
activity become much less than usual.
The SF-36 v2 is a subjective health survey; our results
showed that no close association occurs between subjec-
tive and objective data such as liver-function tests, except
in the early post-stem therapy phase. These observation
agree with those of Kondo et al. [3], but on following up
our patients, the issue becomes different, and this may be
because no follow-up data were acquired in the Kondo
study; moreover, this is also attributed to the difference
in the studied groups. In Kondo et al. [3], the study
group was hepatocellular carcinoma patients. Conversely,
some significant relations between the SF-36 v2 domain
scores and laboratory data were detected in our studied
group of patients. A relation exists between SF-36 v2
domains after 1 year of therapy; PCS, MCS, and RP with
AST after 3 months of therapy; ALT before therapy, and
ALT after 1 month of therapy, respectively. A relation
exists between the laboratory data before therapy and
AST, ALT, and total bilirubin and MCS after 6 months,
PCS after 3 months, and RP after 1 year of therapy.
After 1 year of follow-up of both SCT and SMT group,
mortality was reported in three cases (6%) of the SCT
group (I), whereas 19 (38%) cases of the SMT group (II),
with a statistically significant difference between the mean
survival times of both groups and no malignancy cases
reported in the SCT group (I) after treatment all through
the follow-up period. This difference agrees with what was
reported in Nouman et al. [8], but with lower mortality
rates in the stem cell-treated group of patients.
Figure 5 Follow-up data from our previous study. Changes in serum albumin (A), serum bilirubin (B), prothrombin concentration (C),
aspartate transaminase values (D), alanine transaminase values (E), in both control and treated groups. Pre, pretreatment; 1st, first month; 2nd,
second month; 3rd, third month; 6th, sixth month after treatment.
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This study suggests that the SCT patient finds the
overall experience to be a positive one. The study also
allowed us to critically examine the various aspects of
our patient-evaluation process and to develop recom-
mendations for future use. Some of the major sugges-
tions derived from this study are as follows: (a) It
should be stressed that significant postoperative pain
will occur, but it can be controlled; (2) follow-up at an
SCT clinic should be provided for a 1-year period, when
possible, to allow the detection of late-occurring compli-
cations related to therapy that may go unrecognized in
other settings; and (c) donors should be provided with a
realistic assessment of what the SCT outcome is likely
to be.
A potential weakness in our method of evaluating
SCT recipient quality of life is that a member of the
SCT team had conducted the surveys by himself. This
approach clearly results in a high rate of survey compli-
ance, but it may also deter some patients from answer-
ing sensitive questions truthfully, as a clear association
between the respondent and answer by the physician is
possible. Currently, we are considering providing the
donors each with a short questionnaire and a stamped,
self-addressed envelope. They will be asked to complete
the survey and return it anonymously.
The results of our study showed no influence of dia-
betes mellitus on the HRQoL scores of patients who
were subjected to SCT before therapy or after therapy
during the period of follow-up, where the SF-36 v2
domains scores are insignificantly different in diabetic
patients than those with no diabetes. This does not
agree with the concept represented in 2000 by William
H. Polonsky [18]. This may be explained because the
diabetes patients in our study were well controlled with
either insulin or oral hypoglycemic drugs; moreover, no
diabetic complications were encountered in our studied
group.
Conclusions
In contrast to the influence of medical treatment, SCT
improves the SF-36 v2 scoring system across time. This
improvement is not completely dependent on the
changes in the objective clinical variables that occurred
during the same follow-up period, raising the question
to include a new parameter to reflect the liver condition
differently from the commonly used ones. No significant
influence of diabetes mellitus on SF-36 v2 scores was
detected during the follow-up period, and it is recom-
mended to study the influence of diabetes mellitus on
the HRQoL in patients receiving SCT in a larger cohort
of patients. Improved survival of patients occurs after
SCT.
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